Aligos Q2 net loss $15.9M, cash $122.9M; Phase 2 HBV study dosing imminent

Aligos Therapeutics, Inc.

2025-Q2 EPS reported $2.90 revenue$1,276,000

Net loss of $15.9M ($1.53/sh) vs net income of $5.1M ($0.81/sh) in Q2 2024, driven by change in warrant fair value.
Cash, cash equivalents and investments $122.9M as of June 30, 2025, expected to fund operations into H2 2026.
Phase 2 B-SUPREME study of ALG-000184 (HBV) starting; interim data expected 2026, topline 2027.
ALG-055009 (MASH) Phase 2a data presented; company evaluating partnership options for continued development.
R&D expenses fell to $14.0M from $21.1M YoY due to MASH trial completion, offset by HBV program spend.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.